Pages that link to "Q34038946"
Jump to navigation
Jump to search
The following pages link to Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women (Q34038946):
Displaying 50 items.
- Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. (Q31076192) (← links)
- Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay (Q33723312) (← links)
- Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection (Q33947813) (← links)
- Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine (Q34032367) (← links)
- Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections (Q34267472) (← links)
- Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins (Q34492140) (← links)
- Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection (Q34553461) (← links)
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection (Q34612818) (← links)
- A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls (Q34708325) (← links)
- Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial (Q34738944) (← links)
- Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection (Q34786808) (← links)
- A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study (Q35088658) (← links)
- Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus (Q35109451) (← links)
- Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker (Q35190027) (← links)
- Secreted blood reporters: insights and applications (Q35294368) (← links)
- A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection (Q35599310) (← links)
- Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine (Q35818648) (← links)
- A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays (Q35887709) (← links)
- Therapeutic cancer vaccines: current status and moving forward (Q35894347) (← links)
- Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera (Q35985515) (← links)
- Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels (Q36054504) (← links)
- Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies (Q36269739) (← links)
- Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials (Q36305499) (← links)
- Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®) (Q36480943) (← links)
- Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids (Q36750553) (← links)
- Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy (Q36988090) (← links)
- Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women (Q37318334) (← links)
- Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination (Q37384735) (← links)
- Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. (Q37388424) (← links)
- Comparison of antibody responses to human papillomavirus vaccination as measured by three assays (Q37466826) (← links)
- Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities (Q37671423) (← links)
- Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial (Q37683122) (← links)
- HPV disease transmission protection and control (Q37705703) (← links)
- Assessment of mucosal immunity to HIV-1. (Q37724856) (← links)
- Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems (Q37867102) (← links)
- Human papillomavirus vaccines--immune responses (Q38064069) (← links)
- Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging (Q38460217) (← links)
- Functional assessment and structural basis of antibody binding to human papillomavirus capsid (Q38671633) (← links)
- Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis (Q38716676) (← links)
- The prevalence of HPV infections in HPV-vaccinated women from the general population. (Q40291505) (← links)
- Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine (Q40576411) (← links)
- Therapeutic Cancer Vaccines (Q40728648) (← links)
- Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial (Q41145359) (← links)
- Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule (Q42224633) (← links)
- Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial (Q42257816) (← links)
- Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years (Q43452461) (← links)
- MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). (Q46102734) (← links)
- Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development (Q47549756) (← links)
- Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges (Q59349533) (← links)
- Therapeutic cancer vaccines. (Q64924726) (← links)